



Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis

Hiroki Maruyama, MD, PhD¹, Kaori Miyata, BA², Mariko Mikame, BEd¹, Atsumi Taguchi, PhD¹, Chu Guili, MD, PhD¹, Masaru Shimura, MD³, Kei Murayama, MD, PhD³, Takeshi Inoue, MD, PhD⁴, Saori Yamamoto, MD, PhD⁵, Koichi Tamita, MD⁶, Toshihiro Kawasaki, RDCS⁶, Jun Kajihara, MD⁷, Akifumi Onishi, MD⁸, Hitoshi Sugiyama, MD, PhD⁸, Teiko Sakai, MD⁹, Ichijiro Murata, MD, PhD¹⁰, Takamasa Oda, MD, PhD¹¹, Shigeru Toyoda, MD, PhD¹², Kenichiro Hanawa, MD, PhD¹³, Takeo Fujimura, MD, PhD¹⁴, Shigehisa Ura, MD¹⁵, Mimiko Matsumura, MD¹⁶, Hideki Takano, MD, PhD¹⁶, Satoshi Yamashita, MD¹⁷, Gaku Matsukura, MD¹⁷, Ryushi Tazawa, MD, PhD¹⁸, Tsuyoshi Shiga, MD, PhD¹⁹, Mio Ebato, MD, PhD²⁰, Hiroshi Satoh, MD, PhD²¹ and Satoshi Ishii, PhD²²

Genetics in Medicine (2019) 21:1900; https://doi.org/10.1038/s41436-018-0258-3

Correction to: Genetics in Medicine; https://doi.org/10.1038/gim.2018.31; published online 15 March 2018

The PDF and HTML versions of the article have been updated to include the Creative Commons Attribution 4.0 International License information.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

The Author(s) 2018

Published online: 12 September 2018

¹Department of Clinical Nephroscience, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan; ²Sanofi K.K., Sanofi Genzyme Medical Operations, Rare Disease Medical, Medical Science Liaison, Tokyo, Japan; ³Department of Metabolism, Chiba Children's Hospital, Chiba, Japan; ⁴Department of Pediatrics, Dokkyo Medical University Koshigaya Hospital, Koshigaya, Japan; ⁵Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan; ⁶Nishinomiya Watanabe Cardiovascular Center, Nishinomiya, Japan; ⁷Department of Cardiology, Fujinomiya City General Hospital, Fujinomiya, Japan; ⁸Department of Human Resource Development of Dialysis Therapy for Kidney Disease, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan; ⁹Sukoyaka Clinic, Gifu, Japan; ¹⁰Department of Chronic Kidney Disease, Gifu University Graduate School of Medicine, Gifu, Japan; ¹¹Yamaguchi Prefectural Grand Medical Center, Hofu, Japan; ¹²Department of Cardiology, Internal Medicine, Iwaki Kyoritsu General Hospital, Iwaki, Japan; ¹³Department of Nephrology, Kashiwazaki General Hospital and Medical Center, Kashiwazaki, Japan; ¹⁵Division of Neurology, Japanese Red Cross Asahikawa Hospital, Asahikawa, Japan; ¹⁶Department of Nephrology, Tokyo Teishin Hospital, Tokyo, Japan; ¹⁷Department of Cardiology, Japanese Red Cross Hamamatsu Hospital, Hamamatsu, Japan; ¹⁸Division of Medical Genetics, Bioscience Medical Research Center, Niigata University Medical and Dental Hospital, Niigata, Japan; ¹⁹Department of Cardiology, Tokyo Women's Medical University, Tokyo, Japan; ²⁰Division of Cardiology, Showa University Fujigaoka Hospital, Yokohama, Japan; ²¹Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu, Japan; ²²Glyco Pharma Corporation, Oita, Japan